Patients with glaucoma treated with iDose TR experienced sustained IOP reductions, according to a press release from Glaukos.
The company announced the positive data along with other clinical updates for the iDose platform.
In a 36-month follow-up analysis from two phase 3 pivotal clinical trials, 70% of patients who underwent treatment with the iDose TR (travoprost intracameral implant) remained well controlled on the same or fewer IOP-lowering topical medications compared with 58% of patients in the control group who received timolol. The implant also demonstrated tolerability and a favorable